Bipartisan Deal Includes Important Step to Control Medicaid Drug Prices, But More Efforts Are Needed

Today, the Commonwealth Fund published a blog post on the Bipartisan Budget Act of 2018, which will have an impact on Medicaid drug prices.

The Bipartisan Budget Act of 2018 didn’t include proposed legislation such as, the CREATES Act, which is designed to curb brand-name drug manufacturers’ use of anticompetitive tactics to block access to generic drugs, but included a wide range of policies to reduce prescription drug prices and costs. Specifically, it made technical corrections to line-extension drugs and included two provisions that save Medicaid beneficiaries and the federal government money.

The Bipartisan Budget took the first step to controlling Medicaid drug prices, fixing the Medicaid rebate for line-extension drugs, more quickly closing the Medicare Part D coverage gap, and making biosimilars affordable to Medicare beneficiaries, but we must continue working towards policies, such as the CREATES Act, that balance the incentives for drug innovation and competition and ensure prescription drugs remain affordable to all who need them.

Check out the full blog post here.